Why Does Immunotherapy Cost — So Much More Than Surgery

Yes, this gap is normal and not a sign of overbilling. Surgery is a single procedure charged once — the operating theatre, the surgeon and a short hospital stay. Immunotherapy is a medicine given repeatedly over months, and each infusion carries its own drug cost on top of the hospital charges. Add up several cycles and the total naturally climbs far higher than one surgery bill, even though nothing was overcharged along the way.

Surgery happens once, so it can be priced as a single package. Immunotherapy works differently — the medicine is bought and given fresh at every visit, so each cycle is billed on its own. A typical course involves several cycles spaced a few weeks apart, so the family sees a new bill each time rather than one number upfront. This is why hospitals can only give a per-cycle estimate, not a fixed total, before treatment starts.

There is no single number — it depends on the individual and the type of skin cancer. Most oncologists give a first block of cycles, then order a scan to see whether the cancer has shrunk, stayed the same, or grown. If it is responding, cycles continue on the same schedule. If not, the tumour board changes the plan rather than continuing an expensive treatment that isn't helping. This check-in point is built into the cost, not an extra.

No. Most skin cancers are found early and localised, and surgery alone is enough to treat them — these patients never need immunotherapy or its cost. Immunotherapy is generally reserved for cancer that has spread beyond the skin, come back after earlier treatment, or carries a high risk of returning. Whether it is even offered depends on the stage and biology of the individual cancer, decided by the treating oncologist and tumour board, not by patient or family preference.

The decision is made by the oncologist and the tumour board, not by the family or by cost. They look at the stage of the skin cancer, whether it has spread, results from tests done on the tumour tissue, and the patient's overall health. Immunotherapy is only recommended when it is likely to help — it is never offered as a default upgrade from surgery, and a second opinion is always reasonable if a family wants one before deciding.

This page explains why the cost looks the way it does; a separate guide in this series covers how families actually bring that cost down — through Aarogyasri and other government schemes where eligible, insurance cashless approval, EMI options, and manufacturer or NGO drug-assistance programmes. If immunotherapy has been recommended for you or a family member, ask your treating team which of these apply to your specific case before assuming the full amount is out of reach.